B-cell lymphoma 6 (BCL6) is a transcriptional repressor that regulates the differentiation of B lymphocytes and mediates the formation of germinal centers (GCs) by recruiting corepressors through the BTB domain of BCL6. Physiological processes regulated by BCL6 involve cell activation, differentiation, DNA damage, and apoptosis. BCL6 is highly expressed when the gene is mutated, leading to the malignant proliferation of cells and drives tumorigenesis. BCL6 overexpression is closely correlated with tumorigenesis in diffuse large B-cell lymphoma (DLBCL) and other lymphomas, and BCL6 inhibitors can effectively inhibit some lymphomas and overcome resistance. Therefore, targeting BCL6 might be a promising therapeutic strategy for treating lymphomas. Herein, we comprehensively review the latest development of BCL6 inhibitors in diffuse large B-cell lymphoma and discuss the overview of the pharmacophores of BCL6 inhibitors and their efficacies in vitro and in vivo. Additionally, the current advances in BCL6 degraders are provided.

中文翻译：

---

B 细胞淋巴瘤 6 抑制剂：弥漫性大 B 细胞淋巴瘤药物开发的当前进展和前景

B 细胞淋巴瘤 6 (BCL6) 是一种转录抑制因子，可调节 B 淋巴细胞的分化，并通过 BCL6 的 BTB 结构域募集辅助抑制因子来介导生发中心 (GC) 的形成。BCL6 调控的生理过程涉及细胞活化、分化、DNA 损伤和细胞凋亡。BCL6基因发生突变时高表达，导致细胞恶性增殖并驱动肿瘤发生。BCL6 过表达与弥漫性大 B 细胞淋巴瘤 (DLBCL) 和其他淋巴瘤的肿瘤发生密切相关，BCL6 抑制剂可以有效抑制某些淋巴瘤并克服耐药性。因此，靶向 BCL6 可能是治疗淋巴瘤的一种有前途的治疗策略。在此处，体外和体内。此外，还提供了 BCL6 降解剂的最新进展。